Cite
MLA Citation
Sophie Wildsmith et al.. “266 Tumour mutation burden (TMB) and efficacy outcomes in the phase III DANUBE study of advanced urothelial carcinoma (UC).” Journal for immunotherapy of cancer, vol. 8, n.d., pp. A163–A164. http://access.bl.uk/ark:/81055/vdc_100144731239.0x000003